賓達汀凍晶注射劑

Country: Tajwan

Lingwa: Ċiniż

Sors: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Ingredjent attiv:

BENDAMUSTINE HYDROCHLORIDE

Disponibbli minn:

健喬信元醫藥生技股份有限公司 新竹縣湖口鄉工業一路6號 (43199950)

Kodiċi ATC:

L01AA09

Għamla farmaċewtika:

凍晶注射劑

Kompożizzjoni:

BENDAMUSTINE HYDROCHLORIDE (1004002510) MG; TERTIARY-BUTYL ALCOHOL (9600208100) MG

Unitajiet fil-pakkett:

盒裝

Klassi:

製　劑

Tip ta 'preskrizzjoni:

限由醫師使用

Manifatturat minn:

INTAS PHARMACEUTICALS LIMITED PLOT NO. 5 TO 14, PHARMEZ, NEAR VILLAGE MATODA, TAL: SANAND, CITY: MATODA, DIST: AHMEDABAD, GUJARAT STATE, INDIA IN

Żona terapewtika:

bendamustine

Indikazzjonijiet terapewtiċi:

1.Binet分類stage B及C之慢性淋巴球白血病(chronic lymphocytic leukemia,CLL)。2.曾接受至少一種化療之和緩性非何杰金氏淋巴瘤，六個月內曾以rituximab治療失敗之單一治療。3.Bendamustine合併Rituximab適用於先前未曾接受治療的CD20陽性、第 III / IV 期和緩性非何杰金氏淋巴癌(non-hodgkin lymphoma, NHL)。Bendamustine合併Rituximab適用於先前未曾接受治療且不適合自體幹細胞移植的第 III / IV 期被套細胞淋巴癌(mantle cell lymphoma, MCL)。

Sommarju tal-prodott:

有效日期: 2028/08/09; 英文品名: Bendine Powder for Solution for Infusion

Data ta 'l-awtorizzazzjoni:

2023-08-09